Relationship Between Hepatitis C Infection and Treatment Status and Coronavirus Disease 2019–Related Hospitalizations in Georgia-Reference-Cited by-同舟云学术

Relationship Between Hepatitis C Infection and Treatment Status and Coronavirus Disease 2019–Related Hospitalizations in Georgia

Published:2024-03-01 Issue: Volume: Page:
ISSN:0022-1899
Container-title:The Journal of Infectious Diseases
language:en
Short-container-title:

Author:

Aslanikashvili Ana¹^ORCID,Rylander Charlotta¹^ORCID,Manjavidze Tinatin¹²^ORCID,Gamkrelidze Amiran³^ORCID,Baliashvili Davit⁴^ORCID,Anda Erik Eik¹^ORCID

Affiliation:

1. Department of Community Medicine, University of Tromsø—The Arctic University of Norway , Tromsø , Norway

2. Department of Medical Statistics, National Center for Disease Control and Public Health Georgia , Tbilisi , Georgia

3. School of Health Sciences, University of Georgia , Tbilisi , Georgia

4. Task Force for Global Health , Tbilisi , Georgia

Abstract

Abstract Background The aim of this study was to evaluate the impact of hepatitis C virus (HCV) infection and treatment status on coronavirus disease 2019 (COVID-19)–related hospitalizations in Georgia. Methods We analyzed 2020–2021 Georgian health registry data for COVID-19–positive individuals and categorized the data by HCV infection and treatment status. Logistic regression was used to assess the strengths of the associations. Results Treated individuals with HCV had lower odds of COVID-19–related hospitalization compared to anti-HCV-negative individuals, while untreated HCV-viremic and anti-HCV-positive nonviremic individuals had higher odds. Conclusions HCV treatment prior to COVID-19 infection was associated with lower odds of COVID-19–related hospitalization, highlighting the benefits of HCV management in the context of the pandemic.

Funder

University of Tromsø—The Arctic University of Norway

Publisher

Oxford University Press (OUP)

Link

https://academic.oup.com/jid/advance-article-pdf/doi/10.1093/infdis/jiae103/57080390/jiae103.pdf

Reference15 articles.

1. Global reporting of progress towards elimination of hepatitis B and hepatitis C;Cui;Lancet Gastroenterol Hepatol,2023

2. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial;Lawitz;Lancet,2014

3. Are nucleotide inhibitors, already used for treating hepatitis C virus infection, a potential option for the treatment of COVID-19 compared with standard of care? A literature review;Spera;World J Virol,2021